Have a feature idea you'd love to see implemented?
Let us know!
PRLD Prelude Therapeutics Inc
Price (delayed)
$0.9672
Market cap
$53.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$56.19M
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective
Highlights
The EPS has increased by 18% year-on-year
The quick ratio has contracted by 49% YoY and by 10% from the previous quarter
The equity has declined by 34% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of PRLD
Market
Valuations
Earnings
Shares outstanding
55.04M
Market cap
$53.23M
Enterprise value
$56.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$131.52M
EBITDA
-$128.09M
Free cash flow
-$107.56M
Per share
Balance sheet
Liquidity
EPS
-$1.78
Free cash flow per share
-$1.42
Book value per share
$2.84
Revenue per share
$0
TBVPS
$2.6
Total assets
$197.22M
Total liabilities
$40.79M
Debt
$18.14M
Equity
$156.43M
Working capital
$134.16M
Debt to equity
0.12
Current ratio
7.04
Quick ratio
7.09
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.6%
Return on equity
-66.9%
Return on invested capital
-63.6%
Return on capital employed
-75.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRLD stock price
How has the Prelude Therapeutics stock price performed over time
Intraday
0.57%
1 week
-6.1%
1 month
-45.66%
1 year
-70.06%
YTD
-77.35%
QTD
-53.28%
Financial performance
How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$146.26M
Net income
-$131.52M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 14% year-on-year and by 2.8% since the previous quarter
Prelude Therapeutics's net income has decreased by 12% YoY
Growth
What is Prelude Therapeutics's growth rate over time
Valuation
What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
0.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 18% year-on-year
The stock's P/B is 88% below its 5-year quarterly average of 2.9 and 66% below its last 4 quarters average of 1.0
The equity has declined by 34% year-on-year and by 14% since the previous quarter
Efficiency
How efficient is Prelude Therapeutics business performance
PRLD's return on equity is down by 24% year-on-year and by 12% since the previous quarter
The ROA has contracted by 13% YoY and by 8% from the previous quarter
Prelude Therapeutics's ROIC has decreased by 7% from the previous quarter and by 6% YoY
Dividends
What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRLD.
Financial health
How did Prelude Therapeutics financials performed over time
PRLD's total liabilities has soared by 101% YoY but it is down by 2.9% from the previous quarter
The quick ratio has contracted by 49% YoY and by 10% from the previous quarter
The debt is 88% lower than the equity
The equity has declined by 34% year-on-year and by 14% since the previous quarter
PRLD's debt to equity is up by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.